Vega Investment Solutions Has $1.37 Million Stake in Danaher Corporation $DHR

Vega Investment Solutions lessened its position in shares of Danaher Corporation (NYSE:DHR) by 76.7% in the second quarter, HoldingsChannel.com reports. The fund owned 6,942 shares of the conglomerate’s stock after selling 22,814 shares during the period. Vega Investment Solutions’ holdings in Danaher were worth $1,371,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Danaher by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock worth $12,004,424,000 after buying an additional 788,499 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after acquiring an additional 612,154 shares during the period. Geode Capital Management LLC grew its stake in shares of Danaher by 0.6% in the second quarter. Geode Capital Management LLC now owns 13,726,194 shares of the conglomerate’s stock worth $2,697,800,000 after purchasing an additional 81,670 shares during the last quarter. Norges Bank acquired a new stake in shares of Danaher in the second quarter valued at about $1,979,503,000. Finally, Generation Investment Management LLP raised its holdings in Danaher by 56.2% during the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock worth $980,914,000 after purchasing an additional 1,787,522 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Transactions at Danaher

In related news, Director Teri List sold 3,298 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the transaction, the director directly owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. This trade represents a 13.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 5,174 shares of Danaher stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the transaction, the senior vice president owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. This trade represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 30,248 shares of company stock worth $6,609,663 over the last quarter. Corporate insiders own 11.20% of the company’s stock.

Danaher Stock Down 0.4%

Danaher stock opened at $226.20 on Monday. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $159.78 billion, a P/E ratio of 46.64, a P/E/G ratio of 4.39 and a beta of 0.89. The firm has a 50 day moving average price of $216.22 and a 200-day moving average price of $204.48. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $258.23.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.17. The business had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.Danaher’s revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.71 earnings per share. As a group, equities analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were issued a dividend of $0.32 per share. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio is 26.39%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price objective (down from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. TD Cowen boosted their target price on shares of Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Rothschild Redb downgraded shares of Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Finally, Wells Fargo & Company reaffirmed a “positive” rating on shares of Danaher in a research report on Thursday, October 23rd. Twenty analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $245.75.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.